FDA Policy/General

Food & Drug Legal Icon Peter Barton Hutt Passes Away at 91

Peter Barton Hutt, former FDA chief counsel who was widely known as the "Dean of the Food and Drug Bar," died on 9/2 at the age of 91. Hutt spent more than six decades shaping the legal and regulatory framework governing drugs, medical devices, foods and other products overseen by the agency. His passing marks the loss of an influential figure whose career bridged government, private practice and legal education. Hutt’s own biography describes a professional life devoted to FDA law, public policy and the development of modern regulatory practices.

Hutt spent almost his entire career at the law firm Covington & Burling. He also served as chief counsel for FDA from 1971 to 1975, a period during which he fundamentally reshaped the agency’s regulatory framework. According to his biography, he helped move FDA from an older model of law enforcement toward modern administrative law, developing procedures and regulatory practices that continue to influence the agency.

Hutt joined Covington & Burling in 1960 and, except for his four years at FDA, remained associated with the firm until his retirement in 2024. His biography says he testified before Congress more than 100 times and worked on legislation ranging from the Drug Amendments of 1962 and the Controlled Substances Act to the Orphan Drug Act, the Nutrition Labeling and Education Act and the 21st Century Cures Act.

Hutt was equally influential as an educator and scholar. Beginning in 1994, he taught Food and Drug Law at Harvard Law School during the winter term, continuing a relationship with the school that spanned more than three decades.

Hutt’s legacy will be measured not only by the laws and regulations he helped create, but also by the scores of lawyers, regulators, academics and industry leaders he influenced. He served on numerous scientific and academic committees, including work with the National Academy of Medicine and presidential advisory groups, and received numerous professional honors during his career.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome